🏛️ Verified NIH Record • Updated 2026-01-15

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (NCT03333343)

A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor receptor- mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).

Who can join: Review the eligibility criteria below.

Location: Novartis Investigative Site — Toronto, Ontario

Age range: 18 Years to 100 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (11 Sites)

  • Novartis Investigative Site — Toronto, Ontario
  • Novartis Investigative Site — Cologne, North Rhine-Westphalia
  • Novartis Investigative Site — Essen,
  • Novartis Investigative Site — Hong Kong,
  • Novartis Investigative Site — Ancona, AN
  • Novartis Investigative Site — Milan, MI
  • Novartis Investigative Site — Rozzano, MI
  • Novartis Investigative Site — Singapore,
  • Novartis Investigative Site — Singapore,
  • Novartis Investigative Site — Tainan,
  • Novartis Investigative Site — Taipei,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in EGFR-mutant Non-small Cell Lung Cancer

Explore by condition: All EGFR-mutant Non-small Cell Lung Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗